The insulin-like growth factor pathway as a target for cancer therapy

Clinical and Translational Oncology

Volumn 12, Issue 5, 2010, Pages 326-338

  López Calderero, Iker ^a   Chávez, Elizabeth Sánchez ^a   García Carbonero, Rocío ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

IGF 1 pathway; Nticancer therapy Monoclonal antibodies; Review; Yrosine kinase inhibitors

Indexed keywords

AMG 479; AVE 1646; AVE 16462; CARBOPLATIN; CETUXIMAB; CIXUTUMUMAB; CP 751871; DEXAMETHASONE; DOCETAXEL; ERLOTINIB; EXEMESTANE; FULVESTRANT; GEMCITABINE; HUMAN MONOCLONAL ANTIBODY; IMC A 12; INSM 18; IRINOTECAN; MK 0646; OSI 906; PACLITAXEL; PANITUMUMAB; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; RI 507; ROBATUMUMAB; SCH 717454; SOMATOMEDIN C; SORAFENIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; XL 228;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ACUTE LYMPHOCYTIC LEUKEMIA; ADRENAL CORTEX CARCINOMA; ANEMIA; ANOREXIA; ASTHENIA; BINDING AFFINITY; BREAST CANCER; CEREBROVASCULAR ACCIDENT; CHILL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DOWNSTREAM PROCESSING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENZYME INHIBITION; EWING SARCOMA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FLUSHING; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERSENSITIVITY REACTION; HYPERTRANSAMINASEMIA; HYPERURICEMIA; HYPOTHYROIDISM; IMPAIRED GLUCOSE TOLERANCE; INFECTION COMPLICATION; LEIOMYOSARCOMA; LIGAND BINDING; LIVER CANCER; LOADING DRUG DOSE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOCYTOPENIA; MULTIPLE MYELOMA; MYELOMA; NAIL DISEASE; NAUSEA; NEOPLASM; NEUROECTODERM TUMOR; NEUROENDOCRINE TUMOR; NEUTROPENIA; NONHODGKIN LYMPHOMA; PANCREAS CANCER; PARESTHESIA; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PRURITUS; PSORIASIS; PURPURA; RASH; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SOLID TUMOR; SYNCOPE; THROMBOCYTOPENIA; TUMOR LYSIS SYNDROME; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; SOMATOMEDINS;

EID: 77955936622     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-010-0514-8     Document Type: Review

References (85)

1. Tao Y, Pinzi V, Bourhis J et al (2007) Mechanisms of Disease: signalling of the insulin-like growth factor 1 receptor pathway - therapeutic perspectives in cancer. Natur Rev Clin Pract Oncol 4:591-602
2. M. Pollak (2008) Targeting insulin and insulinlike growth factor signalling in oncology. Curr Opin Pharmacol 8:384-392
3. Lelbach A, Muzes G, Feher J (2005) The insulinlike growth factor system: IGFs, IGF-binding proteins and IGFBP-proteases. Acta Physiol Hung 92:97-107
4. Froesch ER, Burgi H, Ramseiser EB et al (1963) Antibody-suppressible and nonsuppressible insulin- like activities in human serum and their physiologic significance. J Clin Invest 42:1816-1834
5. Pavelic J, Matijevic T, Knezevic J (2007) Biological and physiological aspects of action of insulinlike growth factor peptide family. Indian J Med Res 125:511-522
6. Gauguin L, Klaproth B, Sajid W et al (2008) Structural basis for the lower affinity of the insulin- like growth factors for the insulin receptor. J Biol Chem 283:2604-2613
7. Benyoucef S, Surinya KH, Hadaschik D et al (2007) Characterization of insulin/IGF hybrid receptors: contributions of the insulin receptor L2 and Fn1 domains and the alternatively spliced exon 11 sequence to ligand binding and receptor activation. Biochem J 403:603-613
8. Kornfeld S (1992) Structure and function of the mannose-6-phosphate/ insulin like growth factor II receptors. Annu Rev Biochem 61:307-330
9. Belfiore A (2007) The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des 13:671-686
10. Clemmons DR (2001) Use of mutagenesis to probe IGF-binding protein structure/function relationships. Endocr Rev 22:800-817
11. Buckbinder L, Talbott R, Velasco-Miguel S et al (1995) Induction of the growth inhibitor IGFbinding protein 3 by p53. Nature 377:646-649
12. De Meyts P, Whittaker J (2002) Structural biology of insulin and IGF-1 receptors: implications for drug design. Nat Rev Drug Discov 1:769-783
13. Kooijman R, Lauf JJ, Kappers AC et al (1995) Insulin- like growth factor induces phosphorylation of immunoreactive insulin receptor substrate and its association with phosphatidylinositol-3 kinase in human thymocytes. J Exp Med 182:593-597
14. Shaw RJ and Cantley LC (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441:424-430
15. Paz-Ares L, Blanco-Aparicio C, García-Carbonero R, Carnero A (2009) Inhibiting PI3K as a therapeutic strategy against cancer. Clin Transl Oncol 11:572-579
16. Ma J, Pollak M, Giovannucci E et al (1999) Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I, and IGF-binding protein-3. J Natl Cancer Inst 91:620-625
17. Chan JM, Stampfer MJ, Giovannucci E et al (1998) Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279:563-566
18. Cheng I et al (2006) Common genetic variation in IGF1 and prostate cancer risk in the Multiethnic Cohort. J Natl Cancer Inst 98:123-134
19. Tsuchiya N et al (2006) Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer. J Clin Oncol 24:1982-1989
20. Giovannucci E, Ascherio A, Rimm EB et al (1995) Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med 122:327-334
21. Calle EE, Rodriguez C, Walker-Thurmond K et al (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625-1638
22. Wolpin BM, Meyerhardt JA, Chan AT et al (2009). Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol 27:176-185
23. Ahlgren M, Melbye M, Wohlfahrt J, Sorensen TI (2004) Growth patterns and the risk of breast cancer in women. N Engl J Med 351:1619-1626
24. Osborne, CK, Bolan G, Monaco ME et al (1976) Hormone responsive human breast cancer in longterm tissue culture: effect of insulin. Proc Natl Acad Sci USA 73:4536-4540
25. Heuson JC, Legros N (1972) Influence of insulin deprivation on growth of the 7,12-dimethylbenz(a) anthracene-induced mammary carcinoma in rats subjected to alloxan diabetes and food restriction. Cancer Res 32:226-232
26. Myal Y, Shiu RP, Bhaumick B (1984) Receptor binding and growth-promoting activity of insulinlike growth factors in human breast cancer cells (T-47D) in culture. Cancer Res 44:5486-5490
27. Frasca F, Pandini G, Sciacca L et al (2008) The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem 114:23-37
28. Kaneda A, Wang CJ, Cheong R et al (2007) Enhanced sensitivity to IGF-II signalling links loss of imprinting of IGF2 to increased cell proliferation and tumor risk. Proc Natl Acad Sci USA 104: 20926-20931
29. DiGiovanni J, Kiguchi K, Frijhoff A et al (2000) Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc Natl Acad Sci USA 97:3455-3460
30. Wu Y, Cui K, Miyoshi K et al (2003). Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res 63:4384-4388
31. Majeed N, Blouin MJ, Kaplan-Lefko PJ et al (2005). A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model. Oncogene 24:4736-4740
32. Hadsell DL, Murphy KL, Bonnette SG et al (2000) Cooperative interaction between mutant p53 and des(1-3)IGF-I accelerates mammary tumorigenesis. Oncogene 19:889-898
33. Carboni JM, Lee AV, Hadsell DL et al (2005) Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res 65:3781-3787
34. Sell C, Rubini M, Rubin R et al (1993) Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci USA 90:11217-11221
35. Martin MJ, Melnyk N, Pollard M et al (2006) The insulin-like growth factor I receptor is required for Akt activation and suppression of anoikis in cells transformed by the ETV6- NTRK3 chimeric tyrosine kinase. Mol Cell Biol 26:1754-1769
36. Wiseman LR, Johnson MD, Wakeling AE et al (1993) Type I IGF receptor and acquired tamoxifenresistance in oestrogen-responsive human breast cancer cells. Eur J Cancer 29A:2256-2264
37. Lu Y, Zi X, Zhao Y et al (2001) Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93:1852-1857
38. Kuribayashi A, Kataoka K, Kurabayashi T, Miura M (2004) Evidence that basal activity, but not transactivation, of the epidermal growth factor receptor tyrosine kinase is required for insulin-like growth factor I-induced activation of extracellular signal-regulated kinase in oral carcinoma cells. Endocrinology 145:4976-4984
39. Zhang Q, Thomas SM, Lui VW et al (2006) Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. Proc Natl Acad Sci U S A 103:6901-6906
40. Morgillo F, Woo JK, Kim ES et al (2006) Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 66:10:100-111
41. Ueda S et al (2006) Potential crosstalk between insulin-like growth factor receptor type 1 and epidermal growth factor receptor in progression and metastasis of pancreatic cancer. Mod Pathol 19:788-796
42. Lu Y, Zi X, Zhao Y et al (2001) Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93:1852-1857
43. Nahta R, Yuan LX, Zhang B et al (2005) Insulinlike growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 65:11118-11128
44. Chakraborty AK, Liang K, DiGiovanna MP (2008) Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer. Cancer Res 68:1538-1545
45. Harris LN, You F, Schnitt SJ et al (2007) Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res13:1198-1207
46. Wu JD, Haugk K, Woodke L et al (2006) Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J Cell Biochem 99:392-1340
47. Lin HK, Yeh S, Kang HY, Chang C (2001) Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci USA 98:7200-7205
48. Stephen RL, Shaw LE, Larsen C et al (2001) Insulin-like growth factor receptor levels are regulated by cell density and by long term estrogen deprivation in MCF7 human breast cancer cells. J Biol Chem 276:40080-40086
49. Martin LA, Pancholi S, Chan CM et al (2005) The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling. Endocr Relat Cancer 12:1017-1036
50. Campbell RA, Bhat-Nakshatri P, Patel NM et al (2001) Phosphatidylinositol 3-kinase/AKTmediated activation of estrogen receptor alpha: a new model for antiestrogen resistance. J Biol Chem 276:9817-9824
51. Helle SI, Holly JM, Tally M et al (1996) Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients. Int J Cancer 69:335-339
52. Slomiany MG, Black LA, Kibbey MM et al (2006) IGF-1 induced vascular endothelial growth factor secretion in head and neck squamous cell carcinoma. Biochem Biophys Res Commun 342:851-858
53. Li J et al (2005) Upregulation of VEGF-C by androgen depletion: the involvement of IGF-IRFOXO pathway. Oncogene 24:5510-5520
54. Tang Y et al (2003) Vascular endothelial growth factor C expression and lymph node metastasis are regulated by the type I insulin-like growth factor receptor. Cancer Res 63:1166-1171
55. Slomiany MG, Rosenzweig SA (2006) Hypoxiainducible factor-1-dependent and -independent regulation of insulin-like growth factor-1-stimulated vascular endothelial growth factor secretion. J Pharmacol Exp Ther 318:666-675
56. Stearns M et al (2005) Activated Ras enhances insulin-like growth factor I induction of vascular endothelial growth factor in prostate epithelial cells. Cancer Res 65:2085-2088
57. Burroughs KD et al (2003) Phosphatidylinositol 3-kinase and mek1/2 are necessary for insulinlike growth factor-I-induced vascular endothelial growth factor synthesis in prostate epithelial cells: a role for hypoxia-inducible factor-1? Mol Cancer Res 1:312-322
58. Lacy MQ, Alsina M, Fonseca R et al (2008) Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol 26:3196-3203
59. Haluska P, Shaw HM, Batzel GN et al (2007) Phase I dose escalation study of the anti insulinlike growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 13:5834-5840
60. Haluska P, Worden F, Olmos D et al (2010) Safety, tolerability, and pharmacokinetics of the anti- IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol 65:765-773
61. Olmos D, Postel-Vinay S, Molife LR et al (2010) Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol 11:129-135
62. Attard G, Fong PC, Molife R et al (2006). Phase I trial involving the pharmacodynamic (PD) study of circulating tumour cells, of CP-751,871 (C), a monoclonal antibody against the insulinlike growth factor 1 receptor (IGF-1R), with docetaxel (D) in patients (p) with advanced cancer. J Clin Oncol 24:126s
63. Pollak M, Eisenberg P, Karp D et al (2007). Safety and tolerability of the anti-IGF-I receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in patients with advanced solid tumors. AACR Meeting Abstracts (abstract LB-343)
64. Karp DD, Paz-Ares LG, Novello S et al (2009) Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 27:2516-2522
65. Higano CS Yu EY, Whiting SH et al (2007) A phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid tumors. J Clin Oncol 25 ASCO Annual Meeting Proceedings Abstr 3505
66. Malempati S, Weigel B, Ingle AM et al (2009) A phase I trial and pharmacokinetic study of IMC-A12 in pediatric patients with relapsed/ refractory solid tumors: A Children's Oncology Group Phase I Consortium study. ASCO Annual Meeting. J Clin Oncol 27:15s (abstr 10013)
67. Higano C, Alumkal J, Ryan CJ et al (2009) A phase II study evaluating the efficacy and safety of single agent IMC-A12, a monoclonal antibody (MAb), against the insulin-like growth factor-1 receptor ( IGF-IR), as monotherapy in patient with metastatic, asymptomatic castrationresistant prostate cancer (CRCP). ASCO Annual Meeting. J Clin Oncol 27:15s (abstr 5142)
68. Tolcher AW, Sarantopoulos J, Patnaik A et al (2009) A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor receptor 1. J Clin Oncol 27:5800-5807
69. Sarantopoulos J, Mita AC, Mulay M et al (2008) A phase IB study of AMG 479, a type 1 insulinlike growth factor receptor (IGF1R) antibody, in combination with panitumumab (P) or gemcitabine (G). J Clin Oncol 26:173s
70. Atzori, F, Tabernero J, Cervantes A et al (2008) A phase I, pharmacokinetic and pharmacodynamic study of weekly MK-0646, and insulinlike growth factor-1 receptor monoclonal antibody in patients with advanced solid tumors. J Clin Oncol 26:157s
71. Hidalgo M, Tirado Gomez M, Lewis N et al (2008) A phase I study of MK-0646, a humanized monoclonal antibody against the insulinlike growth factor receptor type 1 in advanced solid tumor patients in a q2 wk schedule. J Clin Oncol 26:158s
72. Javle M, Varadhachary G, Bhosale P et al (2010) Phase I study of MK-0646, a humanized monoclonal antibody against IGF-1R in combination with gemcitabine or gemcitabine plus erlotinib for advanced previously untreated pancreatic cancer. ASCO Gastrointestinal Cancers Symposium (abstract 131)
73. Moreau P, Hulin C, Facon T et al (2007) Phase I study of AVE1642 anti IGF-1R monoclonal antibody in patients with advanced multiple myeloma. ASH Meeting (abstr 1166)
74. Tolcher AW, Rothenberg ML, Rodon J et al (2008) A phase I study of AVE1642, a humanized monoclonal antibody IGF-1R antagonist, in patients with advanced solid tumor. J Clin Oncol 26:173s
75. Rodon J, Patnaik A, Stein M et al (2007) A phase I study of q3W R1507, a human monoclonal antibody IGF-1R antagonist in patients with advanced cancer. J Clin Oncol 25:160s
76. Leong S, Gore L, Benjamin R et al (2007) A phase I study of R1507, a human monoclonal antibody IGF-1R (insulin-like growth factor receptor) antagonist given weekly in patients with advanced solid tumors. AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting
77. Patel S, Pappo A, Crowley J et al (2009) A SARC global collaborative phase II trial of R1507, a recombinant human monoclonal anti body to the insulin-like growth factor-1 receptor (IGF1R) in patients with recurrent or refractory sarcomas. ASCO Annual Meeting. J Clin Oncol 27: 15s (abstr 10503)
78. Seraj J, Tsai M, Seiberling M et al (2007). Evaluation of safety and pharmacokinetics of a fully human IGF-1 receptor antibody, SCH 717454, in healthy volunteers. AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting
79. Ryan CJ, Harzstark AH (2008) A pilot doseescalation study of the effects of nordihydroguaiaretic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer. BJU Int 101:436-439
80. Lindsay CR, Chan E, Evans TR et al (2009). Phase I dose escalation study of continuous oral dosing of OSI-906, an insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 27:15s
81. Carden CP, Frentzas S, Langham M et al (2009) Preliminary activity in adrenocortical tumor in phase I dose escalation study of intermittent oral dosing of OSI-906, a small molecule insulinlike growth factor-1 receptor tyrosine kinase inhibitor in patients with advanced solid tumors. ASCO Annual Meeting. J clin Oncol 27:15s (abstr 3544)
82. Britten C, Smith D, Bui L et al (2008) A phase I dose de-escalation study of XL228, a potent IGFIR/src inhibitor in patients with advanced malignancies. EORTCNCI-AACR symposium on Molecular Targets and Cancer Therapeutics Congress
83. Cortes J, Paquette R, Talpaz M et al (2008) Preliminary clinical activity in a phase I trial of the BCR-ABL/IGF-1R/aurora kinase inhibitor XL228 in patients with Ph+ leukemias with either failure to multiple TKI therapies or with T315I mutation. ASH Annual Meeting
84. Yin D, Paccagnella M, Lacy M et al (2008) Population pharmacokinetics of CP-751,871, a monoclonal antibody against IGF-1 receptor, in patients with multiple myeloma or solid tumors. ASCO Annual Meeting. J Clin Oncol 26 (abstr 2524)
85. Gualberto A, Dolled-Filhart P, Hixon M et al (2009) Molecular bases for sensitivity to figitumumab (CP-751,871) in NSCLC. ASCO Annual Meeting. J Clin Oncol 27:15s (abstr 8091)